<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130828</url>
  </required_header>
  <id_info>
    <org_study_id>REC.62-404-14-1</org_study_id>
    <nct_id>NCT04130828</nct_id>
  </id_info>
  <brief_title>Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia</brief_title>
  <official_title>Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Thai Society of Hematology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency anemia is a global health problem and the most common cause of anemia
      worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a
      multitude of symptoms including fatigue, dyspnea on exertion, dysphagia, pallor,
      palpitations, headaches, tinnitus, taste disturbance and pica. Oral iron supplementation is
      associated with increasing hemoglobin in multiple studies in women, pregnant women and
      elderly patients. However, the optimal dose and frequency of oral iron supplementation for
      treatment remains unclear. The current proposed study attempts to address this gap in the
      literature.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patient who achieved hemoglobin target</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hemoglobin achieved 12 g/dL in women, 13 g/dL in men and or increased 1g/dL/4weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Thrice-weekly group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferrous fumarate 200 mg PO PC Thrice-weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrice-daily group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferrous fumarate 200 mg PO PC Thrice-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Fumarate</intervention_name>
    <description>Ferrous fumarate 200 mg PO PC</description>
    <arm_group_label>Thrice-daily group</arm_group_label>
    <arm_group_label>Thrice-weekly group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60 years

          -  Outpatients with iron deficiency anemia defined as hemoglobin less than 12 g/dL in
             women or 13 g/dL in men; AND ferritin less than 30 ng/mL

        Exclusion Criteria:

          -  Allergy to iron

          -  Allergy to albendazole

          -  Currently pregnancy

          -  Currently breastfeeding

          -  Known history of inflammatory bowel disease, celiac disease, inherited bleeding
             disorder, solid cancer, hematologic cancer or thalassemia

          -  Renal impairment or glomerular filtration rate less than 30 ml/min/1.73m2

          -  Hepatic impairment or Child Pugh score more than 7

          -  Active bleeding define hemoglobin decrease more than 2 g/dL

          -  Multivitamin and mineral supplement (35 mg or more of elemental iron per day) in 2
             weeks prior to randomization

          -  Non-literate

        Subject withdrawal criteria:

          -  Intolerance to drugs

          -  Active bleeding define hemoglobin decrease more than 2 g/dL

          -  Major surgery

          -  Blood transfusion

          -  Loss follow-up more than 2 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Siddhibhong Jongkraijakra, Doctor of Pharmacy</last_name>
    <phone>66896441419</phone>
    <email>siddhibhong.j@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddhibhong Jongkraijakra, Doctor of Pharmacy</last_name>
      <email>siddhibhong.j@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Siddhibhong Jongkraijakra</investigator_full_name>
    <investigator_title>Faculty of Pharmaceutical scienes</investigator_title>
  </responsible_party>
  <keyword>ferrous fumarate</keyword>
  <keyword>oral iron treatment</keyword>
  <keyword>thrice-weekly</keyword>
  <keyword>thrice-daily</keyword>
  <keyword>iron deficiency anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

